NO953832L - Cyclic compounds which can be used as inhibitors of platelet glycoprotein IIb / IIIa - Google Patents

Cyclic compounds which can be used as inhibitors of platelet glycoprotein IIb / IIIa

Info

Publication number
NO953832L
NO953832L NO953832A NO953832A NO953832L NO 953832 L NO953832 L NO 953832L NO 953832 A NO953832 A NO 953832A NO 953832 A NO953832 A NO 953832A NO 953832 L NO953832 L NO 953832L
Authority
NO
Norway
Prior art keywords
cyclic compounds
platelet
glycoprotein iib
iiia
inhibitors
Prior art date
Application number
NO953832A
Other languages
Norwegian (no)
Other versions
NO953832D0 (en
Inventor
William Frank Degrado
Sharon Anne Jackson
Shaker Ahmed Mousa
Anju Parthasarathy
Michael Sworin
Maria Rafalski
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of NO953832D0 publication Critical patent/NO953832D0/en
Publication of NO953832L publication Critical patent/NO953832L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Denne oppfinnelsen vedrører nye, sykliske forbindelser som inneholder karbosykliske ringsystemer, som kan anvendes som antagonister for blod- plateglykoprotein Ilb/IIIa-komplekset, farmasøytiske preparater som inneholder slike sykliske forbindelser sammen med eller uten andre terapeutiske midler, og fremgangsmåter for anvendelse av disse forbindelsene sammen med eller uten andre terapeutiske midler, for inhiberingen av blodplateaggregasjon, som trombolytika og/eller for behand- ling av andre tromboemboliske sykdom- mer. Denne oppfinnelsen vedrører også fremgangsmåter for anvendelse av de sykliske forbindelsene ifølge oppfin- nelsen i kombinasjon med antikoagula- sjonsmidler, slik som warfarin eller heparin, eller ytterligere anti- blodplatemidler, slik som aspirin, piroxicam eller ticlopidin, eller trom- bininhibitorer, slik som borpeptider, hirudin eller argatroban, eller trom- bolytiske midler, slik som vevsplas- minogenaktivator, anistreplase, urokin- ase eller streptokinase, eller kombina- sjoner derav, til behandlingen av trom- boemboliske sykdommer.This invention relates to novel cyclic compounds containing carbocyclic ring systems which can be used as antagonists of the platelet glycoprotein IIb / IIIa complex, pharmaceutical compositions containing such cyclic compounds with or without other therapeutic agents, and methods for using these compounds together. with or without other therapeutic agents, for the inhibition of platelet aggregation, such as thrombolytics and / or for the treatment of other thromboembolic diseases. This invention also relates to methods of using the cyclic compounds of the invention in combination with anticoagulants, such as warfarin or heparin, or additional anti-platelet agents, such as aspirin, piroxicam or ticlopidine, or thrombin inhibitors, such as boron peptides. , hirudin or argatroban, or thrombolytic agents, such as tissue plasminogen activator, anisplase, urokinase or streptokinase, or combinations thereof, for the treatment of thromboembolic diseases.

NO953832A 1993-03-29 1995-09-28 Cyclic compounds which can be used as inhibitors of platelet glycoprotein IIb / IIIa NO953832L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3844893A 1993-03-29 1993-03-29
PCT/US1994/003223 WO1994022910A1 (en) 1993-03-29 1994-03-28 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa

Publications (2)

Publication Number Publication Date
NO953832D0 NO953832D0 (en) 1995-09-28
NO953832L true NO953832L (en) 1995-11-28

Family

ID=21900014

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953832A NO953832L (en) 1993-03-29 1995-09-28 Cyclic compounds which can be used as inhibitors of platelet glycoprotein IIb / IIIa

Country Status (10)

Country Link
EP (1) EP0691987A1 (en)
JP (1) JPH08508498A (en)
AU (1) AU6415894A (en)
CA (1) CA2159070A1 (en)
FI (1) FI954556A0 (en)
HU (1) HUT72896A (en)
NO (1) NO953832L (en)
NZ (1) NZ263456A (en)
PL (1) PL310896A1 (en)
WO (1) WO1994022910A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE174036T1 (en) * 1993-03-29 1998-12-15 Du Pont Merck Pharma PROCESS AND INTERMEDIATE COMPOUNDS FOR PRODUCING PLATES GLYCOPROTEIN IIB/IIIA INHIBITORS
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
BR9713141A (en) * 1996-11-27 2000-02-08 Rhone Poulenc Rorer Pharma Pharmaceutical composition process and kit for the treatment or prevention of a physiological condition associated with an ischemic disorder related to thrombosis and a patient, use of pharmaceutically effective amounts of a compound with anti-xa activity and a platelet aggregating antagonist compound, product containing these compounds, and, use of these compounds.
US6010911A (en) * 1997-04-30 2000-01-04 Medtronic, Inc. Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
PT2118123E (en) 2007-01-31 2016-02-10 Harvard College Stabilized p53 peptides and uses thereof
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
KR102237243B1 (en) 2009-11-10 2021-04-07 알레그로 파마슈티칼스, 인코포레이티드. Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
RU2582678C2 (en) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Peptidomimetic macrocycles
CA2835214C (en) 2011-05-09 2023-08-01 Allegro Pharmaceuticals, Inc. Integrin receptor antagonists and their methods of use
TWI643868B (en) 2011-10-18 2018-12-11 艾利倫治療公司 Peptidomimetic macrocycles
JP6450191B2 (en) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド Peptide mimetic macrocycle
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
KR20170058424A (en) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles and uses thereof
KR102570210B1 (en) 2014-09-24 2023-08-23 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles and formulations thereof
JP2018516844A (en) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636066B1 (en) * 1988-09-02 1991-10-25 Centre Nat Rech Scient CYCLOPEPTIDE DERIVATIVES FOR USE AS SELECTIVE INHIBITORS AGAINST ACTIVE SERINE PROTEASES
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
AU6470590A (en) * 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
IL103252A (en) * 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
FI954556A (en) 1995-09-26
PL310896A1 (en) 1996-01-08
HUT72896A (en) 1996-06-28
FI954556A0 (en) 1995-09-26
EP0691987A1 (en) 1996-01-17
NO953832D0 (en) 1995-09-28
CA2159070A1 (en) 1994-10-13
NZ263456A (en) 1996-11-26
WO1994022910A1 (en) 1994-10-13
HU9502832D0 (en) 1995-11-28
AU6415894A (en) 1994-10-24
JPH08508498A (en) 1996-09-10

Similar Documents

Publication Publication Date Title
NO953832L (en) Cyclic compounds which can be used as inhibitors of platelet glycoprotein IIb / IIIa
Walsh et al. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI
Takatsuka et al. Molecular characterization of L-amino acid oxidase from Agkistrodon halys blomhoffii with special reference to platelet aggregation
DK36991A (en) , And its
Siigur et al. Biochemical characterization of lebetase, a direct-acting fibrinolytic enzyme from Vipera lebetina snake venom
EA199700452A1 (en) NEW ISOXASOLINE AND ISOXAZOL ANTAGONISTS OF FIBRINOGEN RECEPTOR
DK0401508T3 (en) Protease inhibitors, processes for their preparation, and drugs containing them
DK0730590T3 (en) Isoxazoline and isozazole fibrinogen receptor antagonists
Marshall et al. Coagulant and anticoagulant actions of Australian snake venoms
Suntravat et al. cDNA cloning of a snake venom metalloproteinase from the eastern diamondback rattlesnake (Crotalus adamanteus), and the expression of its disintegrin domain with anti-platelet effects
Remold et al. Enhancement of migration inhibitory factor activity by plasma esterase inhibitors
DK0730589T3 (en) Isoxazoline Compounds Useful as Fibrinogen Receptor Antagonists
DK634389A (en) PEPTID, ITS MANUFACTURING AND USE TO PROVIDE HIV PROTEASE
Collen Thrombolytic therapy
Korhonen Fibrinolytic and procoagulant activities of Yersinia pestis and Salmonella enterica
Komiyama et al. Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine
NO941561L (en) Bifunctional urokinase variants with improved fibrinolytic properties and thrombin inhibitory effect
ES2337879T3 (en) DOSAGE PROCEDURE OF SOLUBLE FIBRINE.
Furukawa et al. Factor X converting and thrombin-like activities of Bothrops jararaca snake venom
Chu et al. Purification and characterization of a novel fibrinolytic enzyme from Whitmania pigra Whitman
BRPI0409557A (en) recombinant kallikrein inhibitor protein, DNA sequence, expression vector, host cell, pharmaceutical composition and its use, production method of recombinant kallikrein inhibitor protein and diagnostic kit for detection of kallikrein
Walker et al. The inhibition of tissue activator and urokinase by human plasma
Amel et al. Purification and characterization of a new serine protease (VLCII) isolated from Vipera lebetina venom: Its role in hemostasis
Bang Leeches, snakes, ticks, and vampire bats in today's cardiovascular drug development.
Matsushima et al. Activation of fibrinolysis with the protease from Dermatophagoides farinae